Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vahan Kassabian

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Urology Practice|August 18, 2023
Integrating the Genomic Prostate Score into Clinical Practice WorkflowDavid Albala, Premal J Desai, Vahan Kassabian, et al.
JAMA|January 19, 2006
Surveillance for recurrent bladder cancer using a point-of-care proteomic assayH Barton Grossman, Mark Soloway, Edward Messing, et al.
Advances in Therapy|September 8, 2018
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims AnalysisNeil M Schultz, Scott C Flanders, Samuel Wilson, et al.
Cancer|September 5, 2019
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancerCelestia S Higano, Andrew J Armstrong, A Oliver Sartor, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Urology Practice|August 18, 2023
Integrating the Genomic Prostate Score into Clinical Practice WorkflowDavid Albala, Premal J Desai, Vahan Kassabian, et al.
JAMA|January 19, 2006
Surveillance for recurrent bladder cancer using a point-of-care proteomic assayH Barton Grossman, Mark Soloway, Edward Messing, et al.
Advances in Therapy|September 8, 2018
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims AnalysisNeil M Schultz, Scott C Flanders, Samuel Wilson, et al.
Cancer|September 5, 2019
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancerCelestia S Higano, Andrew J Armstrong, A Oliver Sartor, et al.
Pageof 1